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Background: An increasing number of genetic causes of intellectual disabilities (ID) are 
identifiable by clinical genetic testing, offering the prospect of bespoke patient man-
agement. However, little is known about the practices of psychiatrists and their views 
on genetic testing.
Method: We undertook an online survey of 215 psychiatrists, who were contacted via 
the Royal College of Psychiatrist’s Child and Adolescent and Intellectual Disability 
Psychiatry mailing lists.
Results: In comparison with child and adolescent psychiatrists, intellectual disability 
psychiatrists ordered more genetic tests, referred more patients to genetic services, 
and were overall more confident in the genetic testing process. Respondents tended 
to agree that genetic diagnoses can help patient management; however, management 
changes were infrequently found in clinical practice.
Conclusions: Differences are apparent in the existing views and practices of child and 
adolescent and intellectual disability psychiatrists. Developing training and collabora-
tion with colleagues working in genetic services could help to reduce discrepancies 
and improve clinical practice.
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1  | INTRODUCTION
Approximately 1% of the population has a diagnosis of intellectual 
disability (ID), which is characterized by impairments in both intellec-
tual and adaptive functioning and has its origin in the developmental 
period. Intellectual disability is an aetiologically heterogeneous dis-
order, with both environmental and genetic causes. Rapid advances 
in genomics have resulted in many new genetic causes of intellectual 
disability being delineated (Gilissen et al., 2014). Perhaps the better 
recognized genetic causes of intellectual disability occur when in-
dividuals exhibit a constellation of symptoms indicative of a known 
syndrome. In such instances, a specific genetic test may be indicated, 
for example single gene testing in Fragile X syndrome. However, 
where the individual’s presentation is not clearly suggestive of a spe-
cific syndrome, chromosomal microarray analysis (CMA) is now typi-
cally considered the first line genetic investigation (Miller et al., 2010).
CMA can identify small losses and gains of genetic material. These 
losses (deletions) and gains (duplications) are referred to as copy num-
ber variations (CNVs). Loss or gain of genetic material can, in some 
instances, alter gene function and effect neurodevelopment. Several 
recurrent CNVs are associated with elevated risk for intellectual dis-
ability, as well as other co- morbid phenotypes such as schizophrenia 
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and epilepsy. For example the 22q11.2 deletion syndrome is associ-
ated with intellectual disability, but is also is one of the strongest risk 
factors for psychosis (Schneider et al., 2014).
Individuals with intellectual disability face obstacles accessing 
both physical and mental health services and health inequalities 
have been described (Emerson, Baines, Allerton, & Welch, 2012). 
Understanding the genetic aetiology of intellectual disability could 
help to address some of these inequalities by facilitating individ-
ualized care plans. For example, there are clinical management 
guidelines available for the 22q11.2 deletion syndrome. Screening 
for specific physical health conditions, including cardiac, renal and 
immunology investigations, and a comprehensive mental health as-
sessment are recommended (Habel et al., 2014). Such guidelines 
offer good prospects for early intervention and optimized health 
care, although they are not yet available for every genetic cause of 
intellectual disability.
In the UK, infants and children presenting with developmental 
delay are often seen by paediatricians, who can initiate genetic inves-
tigations and where appropriate refer onto specialist child and ado-
lescent mental health services (CAMHS). Adult services are generally 
provided by specialist intellectual disability psychiatrists. Referrals for 
genetic testing can be made to National Health Service (NHS) Regional 
Genetics Centres (RGCs), which offer clinical genetics expertise in syn-
dromes, cascade testing and counselling. Inequities in access to ge-
netic testing have, however, encouraged the mainstreaming of genetic 
investigations, with an increased emphasis placed on medical special-
ists ordering tests directly (Burton, 2011).
Intellectual disability is often associated with co- morbid psychi-
atric disorders and/or behavioural problems. Recent estimates from 
United Kingdom (UK) primary care records show that approximately 
21% of individuals with intellectual disability have a psychiatric dis-
order, 25% have some record of challenging behaviour, and 49% had 
been prescribed psychotropic drugs (Sheehan et al., 2015). Given that 
investigation of the cause of intellectual disability predominately oc-
curs at diagnosis in childhood, there is a large cohort of adults, many 
with later onset psychiatric disorders, who have not had a diagnostic 
assessment utilizing the latest genetic technologies (Baker, Raymond, 
& Bass, 2012). We recently recruited 202 adults with idiopathic intel-
lectual disability from UK psychiatry services and found that 11% had 
undiagnosed clinically relevant CNVs (Wolfe et al., 2017).
Whilst the role of specialist clinicians in ordering/referring for 
 genetic testing is evolving, little is known about their current views 
and practices. We aimed to explore the attitudes and practices of UK 
psychiatrists working in CAMHS and adult intellectual disability psy-
chiatry services on genetic testing in intellectual disability.
2  | METHOD
Psychiatrists from UK CAMHS and adult intellectual disability psychi-
atry services were surveyed as to their attitudes towards and current 
use of genetic investigations using an online survey.
2.1 | Survey
The questions were developed through consultation with intellec-
tual disability psychiatrists, a clinical geneticist, a genetic counsellor, 
a genetic researcher and a statistician. Following a pilot, a number 
of the questions were amended, and the opportunity for open text 
responses was enabled. The 28- item self- administered survey was 
composed of yes/no responses, multiple choice Likert scale questions, 
numeric outcomes and free text responses (available in the Appendix). 
The survey was programmed not to force answers to questions and 
enable completion of the survey with missing responses. It was ad-
ministered via the online service tool Survey Monkey (SurveyMonkey 
Inc. Palo Alto, California, USA).
2.2 | Participants
The survey was distributed to members of the Faculty of Child and 
Adolescent Psychiatry and members of the Faculty of Psychiatry of 
Intellectual Disability via the Royal College of Psychiatrists’ mailing 
list. Psychiatrists were invited by email to participate in the survey. 
A participation reminder was sent after 1 week. Respondents were 
removed from the analysis if they were junior trainees or listed pro-
fessions other than CAMHS psychiatry and adult intellectual disability 
psychiatry, if they lived outside the UK and if they had not seen any 
patients with intellectual disability in the previous 12 months.
2.3 | Statistical analysis
Quantitative statistical analyses were undertaken using IBM SPSS 
Statistics for Windows, Version 22.0 (IBM Corp, Armonk, NY, USA). 
The analysis compared CAMHS psychiatrists (referred to hence-
forth as child psychiatrists) and adult intellectual disability psychia-
trists (referred to henceforth as intellectual disability psychiatrists). 
Continuous outcome variables were analysed, using a t test where 
the data were normally distributed, and Mann- Whitney U test for 
non- normally distributed data. The chi- squared test was utilized to 
test categorical outcome variables. Binary logistic regression was 
undertaken to test univariable factors related to ordering a genetic 
test. For Likert scale responses, the data were collapsed from 5 
to 3 scale responses by merging “strongly agree” with “agree” and 
“strongly disagree” with “disagree” or “very frequently” with “fre-
quently” and “very rarely” with “rarely.” To compare clinical con-
fidence ratings, a composite confidence score was generated by 
assigning the 5- point Likert scale responses a confidence value 
ranging from 1 for strongly disagree to 5 for strongly agree. These 
scores were then summed across the eight confidence measures 
to obtain an overall composite confidence score. Where analyses 
have been undertaken on a subset of the data set due to missing 
values the number of respondents in the analysis has been indi-
cated. Significance has been set at 0.006 to account for multiple 
testing.
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2.4 | Thematic analysis
Open text responses were thematically coded using Nvivo qualitative 
data analysis software (QSR International Pty Ltd. Version 10, 2012). 
Three open text questions were included in the survey, focusing on 
the benefits and concerns of genetic testing in clinical practice. For 
the word cloud, all open text responses were included, and a word 
frequency analysis was undertaken using Nvivo. Word stemming was 
undertaken to combine variations of words from the same root (e.g., 
genetic and genetics). All words mentioned greater than 5 times, ex-
cluding common words, were inputted into Wordle™ (http://www.
wordle.net/) for the creation of the word cloud.
3  | RESULTS
Responses were received from 215 psychiatrists, comprising 121 child 
psychiatrists (56%) and 94 intellectual disability psychiatrists (44%); 56% 
were females (n = 121). The majority of respondents worked in England 
(n = 170, 80%), followed by Scotland (n = 29, 14%), Wales (n = 9, 4%) 
and Northern Ireland (n = 5, 2%). The majority of respondents worked 
in community teams (n = 115, 57%) followed by specialist assessment 
inpatient units (n = 23, 11%) and specialist referral centres (outpatient) 
(n = 19, 9%). A further 46 respondents (23%) reported that they worked 
in more than one of these settings. The median number of years work-
ing in the speciality was 10 (child psychiatrists 10 years, intellectual dis-
ability psychiatrists 11 years).
3.1 | Attitudes towards genetic testing
Respondents were asked to estimate the percentage of peo-
ple with intellectual disability for whom genetic factors make a 
significant contribution towards the cause of their intellectual disabil-
ity. Estimates from child psychiatrists (Mean = 42%, SD = 24.7, Range = 
2- 100%) were comparable to those of intellectual disability psychia-
trists (Mean = 39.6%, SD = 23.1, Range=3- 90%) (n = 206, Mean dif-
ference	 =	 2.4,	 95%	CI	 (−4.25,	 8.1)	p = .48). However, estimates by 
both child and intellectual disability psychiatrists of the percentage 
of patients on their caseloads with an established genetic diagno-
sis were much lower. Intellectual disability psychiatrists estimated a 
higher percentage of their own patients to have an established genetic 
diagnosis (Median = 10%, Range = 0- 70%) compared to child psy-
chiatrists (Median=5%, Range = 0- 100%), (n = 205, U = 3661.5, Mean 
rank = 120 versus Mean rank = 90, p = <.001).
3.2 | Ordering of genetic tests
More intellectual disability psychiatrists (77%), compared with child 
psychiatrists (56%), had ordered a genetic test in the last 10 years 
(n = 162, χ² = 8.08, p = .004). Respondent’s estimates of the percent-
age of intellectual disability caused by genetic factors did not influ-
ence the likelihood of them ordering a genetic test (n = 157, OR 1.01, 
95% CI (0.99- 1.03), p = .19). The percentage of patients on respond-
ents’ caseloads with an established genetic diagnosis also did not af-
fect the likelihood of ordering a genetic test (n = 156, OR 1.02, 95% 
CI (0.99- 1.05), p = .33).
3.3 | Confidence in the genetic testing process
Respondents were asked how confident they felt in eight aspects 
of the genetic testing process, as presented in Table 1. Child psy-
chiatrists had a lower average total confidence score (Mean = 22.1, 
SD = 6.8) in comparison with intellectual disability psychiatrists (Mean 
= 27.4, SD=5.5). (n = 186, Mean difference = 5.3, 95% CI (3.42, 7.1), 
Psychiatry specialism Disagree
Neither agree 
nor disagree Agree
Knowledge of genetic 
tests
Child 52 (50%) 23 (22%) 30 (29%)
Intellectual disability 11 (14%) 14 (17%) 56 (69%)
Assessing for dysmorphic 
features
Child 34 (32%) 22 (21%) 49 (47%)
Intellectual disability 14 (17%) 16 (20%) 51 (63%)
Assessment of capacity 
to consent
Child 10 (10%) 12 (11%) 83 (79%)
Intellectual disability 2 (3%) 6 (7%) 73 (90%)
Ordering genetic tests Child 55 (52%) 25 (24%) 25 (24%)
Intellectual disability 16 (20%) 27 (33%) 38 (47%)
Interpreting genetic test 
results
Child 70 (67%) 22 (21%) 13 (12%)
Intellectual disability 31 (38%) 22 (27%) 28 (35%)
Feedback to patients Child 43 (41%) 28 (27%) 34 (32%)
Intellectual disability 13 (16%) 16 (20%) 52 (64%)
Feedback to family/
carers
Child 41 (39%) 28 (27%) 36 (34%)
Intellectual disability 14 (17%) 12 (15%) 55 (68%)
Genetic counselling Child 71 (68%) 21 (20%) 13 (12%)
Intellectual disability 36 (44%) 27 (33%) 18 (22%)
TABLE  1 Self rated confidence scores 
of child and intellectual disability 
psychiatrists (n = 186) in eight areas of the 
genetic testing process
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p = <.001). In comparison with child psychiatrists, intellectual disabil-
ity psychiatrists agreed that they were confident in: knowledge of ge-
netic tests (69% versus 29%); assessing for dysmorphic features (63% 
versus 47%); ordering (47% versus 24%) and interpreting genetic tests 
(35% versus 12%); genetic counselling (22% versus 12%) and feeding 
back test results to patients (64% versus 32%) and their families (68% 
versus 34%).
3.4 | Concerns with the genetic testing process
Respondents were asked what their main concerns were in relation 
to the genetic testing process, see Table 2. Both child and intellectual 
disability psychiatrists agreed that lack of available treatment was one 
of the main concerns (58% versus 51% retrospectively). Another main 
concern was lack of resources, 54% of child and intellectual disability 
psychiatrists agreed that this was a concern. Implications for insur-
ance were a bigger concern for child psychiatrists in comparison with 
intellectual disability psychiatrists (50% versus 38%), whereas issues 
around counselling were a bigger concern for intellectual disability 
psychiatrists (53% versus 43%).
3.5 | Feedback of results and clinical management
As seen in Figure 1 both child and intellectual disability psychiatrists 
agreed that a genetic diagnosis is more beneficial for family mem-
bers than patients. In comparison with child psychiatrists, intellectual 
disability psychiatrists were more inclined to agree that a diagnosis 
is beneficial for family members (85% versus 78%) (Figure 1a) and 
patients (58% versus 50%) (Figure 1b).
Respondents were also asked how they fed back results to their 
patients with intellectual disability. Of the 146 respondents eight (5%) 
had utilized videos, 20 (14%) had received input from speech and lan-
guage therapists, 48 (33%) had used easy read materials, and 98 (67%) 
had used none of these aids. Responses were comparable for child and 
intellectual disability psychiatrists.
Figure 2 shows respondents’ views and experiences of clinical man-
agement changes following genetic diagnoses. Respondents agreed 
that a genetic diagnosis would help with patient clinical management 
(75% intellectual disability versus 62% child) (Figure 2a); however, 
few agreed that they had seen frequent management changes in their 
 patients (11% intellectual disability versus 12% child) (Figure 2b).
3.6 | Referral to genetics services
Respondents were asked if they had ever ordered a genetic test or 
made a referral to a clinical genetics service. Those who had made 
a referral were also asked to estimate the number of referrals in last 
year. A significantly higher percentage of intellectual disability psychi-
atrists, compared with child psychiatrists, had ordered a test or made 
a referral (90% versus 68%, n = 214, χ² = 15.92, p = <.001). Intellectual 
disability psychiatrists also referred more patients per year to the ge-
netics clinic compared with child psychiatrists (n = 153, Range = intel-
lectual disability 0- 25, child 0- 10, U = 2161.5, Mean rank = 87 versus 
Mean rank = 67, p = .004).
Respondents were asked what the main reasons for referral to 
clinical genetics services were. Of the 155 respondents, the most fre-
quent reason for referral was presence of dysmorphic features (46% 
child, 57% intellectual disability) followed by intellectual disabilities 
Psychiatry specialism Disagree
Neither agree 
nor disagree Agree
Stigma of patients/
families
Child 42 (39%) 39 (36%) 27 (25%)
Intellectual disability 39 (45%) 21 (24%) 27 (31%)
Lack of available 
treatment
Child 26 (24%) 19 (18%) 62 (58%)
Intellectual disability 27 (31%) 16 (18%) 44 (51%)
Lack of resources Child 23 (22%) 26 (24%) 58 (54%)
Intellectual disability 21 (24%) 19 (22%) 46 (54%)
Implications for 
insurance
Child 23 (22%) 30 (28%) 53 (50%)
Intellectual disability 30 (35%) 24 (28%) 33 (38%)
Misuse of results Child 22 (21%) 39 (37%) 45 (43%)
Intellectual disability 37 (43%) 17 (20%) 32 (37%)
Difficulty obtaining a 
family history
Child 40 (37%) 39 (36%) 28 (26%)
Intellectual disability 27 (31%) 19 (22%) 41 (47%)
Obtaining a sample Child 38 (36%) 37 (71%) 31 (29%)
Intellectual disability 35 (40%) 23 (26%) 29 (33%)
Issues around 
counselling
Child 37 (35%) 24 (22%) 46 (43%)
Intellectual disability 22 (25%) 19 (22%) 46 (53%)
Issues around capacity 
to consent
Child 31 (29%) 32 (30%) 44 (41%)
Intellectual disability 36 (41%) 13 (15%) 38 (44%)
TABLE  2 Concerns child and 
intellectual disability psychiatrists (n = 195) 
report in ten areas of the genetic testing 
process
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(31% child, 38% intellectual disability). The least likely reason for re-
ferral was pharmacological treatment (2% both child and intellectual 
disability).
3.7 | Service structure and training
Both intellectual disability and child psychiatrists agreed that closer 
links with regional genetics services would be helpful (83% versus 
72%, n = 197). Respondents were also in agreement that they would 
prefer to refer to a regional genetics service rather than order a ge-
netic test themselves (child 85%, 77% intellectual disability n = 195). 
Finally, there was a consensus that further training in genetics would 
be beneficial (child 71%, 66% intellectual disability, n = 195).
3.8 | Thematic analysis
Four main themes were identified from the 76 respondents who com-
pleted the open response questions, comprising: family impact, clinical 
management, access to services, and training.
Of the 23 respondents who reported family impact the most 
frequent benefits identified were; relief from guilt and increased un-
derstanding of the patient’s condition, followed by ability to access 
a support group and family planning. Respondents who discussed 
clinical management tended to mention the positive aspects, such 
as tailored medical and psychiatric interventions and clarification of 
syndrome- specific behaviours. Only three respondents stated that 
they did not think a genetic diagnosis was helpful for clinical manage-
ment. One respondent commented “it is something of a paradox that the 
advances in the understanding of genetics and its potential impact upon 
our patient group has not translated into a significant increase in the use of 
genetic testing to help with diagnosis and care planning. I can only surmise 
that the social model of Disability as outlined in Valuing People has steered 
the diagnostic process away from genetic labelling.”
Access to genetics services was mentioned by 22 respondents, 
who described problems with referring to genetics services and the 
variable levels of knowledge of professionals involved in the pathway. 
There was concern that psychiatrists, who have not specialized in ge-
netics, do not have the skills to refer directly for genetic testing. Good 
working relationships with genetics services were said to be a valuable 
resource. Five child psychiatrists stated that they would defer to their 
paediatric colleagues to make decisions about genetic testing.
Several respondents felt that current training in genetics was 
insufficient and is not keeping abreast of technological advances. 
It was suggested that quick reference guides and screening tools 
would be valuable resources to support the decision- making process. 
See Figure 3 for a word cloud of the most frequently used words 
in the open text responses (results from both professional groups 
as responses were comparable for child and intellectual disability 
F IGURE  1 Percentage of child (n = 72) 
and intellectual disability psychiatrists 
(n = 81) who feel that a genetic diagnosis is 
helpful for family members (a) and patients 
with intellectual disability (b)
F IGURE  2 Percentage of child 
(n = 121) and intellectual disability (n = 94) 
psychiatrists who feel that that a genetic 
diagnosis is helpful for patient management 
(a) and who report that genetic information 
has helped their patient management (b) 
(child n = 73, intellectual disability n = 82)
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psychiatrists) and a summary of positive and negative opinions for 
each of the main themes.
4  | DISCUSSION
Our results indicate that the majority of child and intellectual disabil-
ity psychiatrists working with patients with intellectual disability are 
already ordering genetic tests or making referrals to genetics services. 
However, there are several disparities in clinical genetic practices. In 
comparison with child psychiatrists, intellectual disability psychiatrists 
reported the following: a higher number of patients with genetic diag-
noses, greater confidence in the genetic testing process, higher num-
bers of tests ordered and more patients referred per year to genetics 
services.
Respondents were asked to estimate the percentage of intellec-
tual disability caused by genetic factors. The responses varied greatly 
with some respondents estimating as low as 2% and others as high 
as 100%. Although both child and intellectual disability psychiatrists 
had similar mean estimates (39.6% and 42%) of the percentage of in-
tellectual disability caused by genetic factors, these estimates were 
much higher than the actual percentage of patients on caseloads with 
a known genetic diagnosis (median = 10% intellectual disability and 
median=5% child). It is unclear why this disparity exists. It would be 
interesting to investigate whether the clinician responsible for order-
ing genetic testing is communicating the results to other professionals 
involved in the individual’s care. This will be particularly important for 
individuals with intellectual disability and co- morbid diagnoses who 
are under the care of multiple medical professionals.
A high proportion of intellectual disability psychiatrists (77%) 
and just over half of child psychiatrists had directly ordered a ge-
netic test. In comparison with child psychiatrists, intellectual dis-
ability psychiatrists were significantly more likely to order a genetic 
test and also referred more patients to the genetics clinic per year. 
F IGURE  3 Word cloud of words mentioned 5 or more times from open text responses with larger words mentioned more frequently. 
Positive and negative responses from the main themes are displayed in the text boxes
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This may have in part been a reflection of the intellectual disabil-
ity psychiatrist’s greater reported confidence in the genetic testing 
process. As evidenced in Table 1, intellectual disability psychiatrists 
were significantly more confident in all aspects of the testing pro-
cess, apart from capacity testing which is likely to be more complex 
in adulthood. One explanation for intellectual disability psychiatrists 
being more confident and ordering/referring for more genetic tests 
is due to the different structures of child and adult intellectual dis-
ability psychiatry services. Some child psychiatrists reported that 
they would defer to paediatric colleagues for opinions on genetic 
testing.
The survey highlighted a number of barriers to genetic testing 
in clinical intellectual disability services. Both child and intellectual 
disability psychiatrists reported that they were concerned about lack 
of available treatment and resources for genetic testing. Interestingly 
child psychiatrists had specific concerns about implications for in-
surance. The Department of Health has released a moratorium ex-
tending until 2019, whereby the only genetic test required to be 
disclosed is for Huntington’s disease on life insurance sums worth 
more than £500,000 (HMGovernment, 2014). Therefore, results 
from CMA should have no impact on insurance premiums, and this 
misconception could be a barrier to clinicians ordering/referring for 
genetic testing. Intellectual disability psychiatrists expressed con-
cern about issues surrounding counselling. Feedback of genetic di-
agnoses to adults with intellectual disability is understandably more 
complex than feedback to parents of children with intellectual dis-
ability, and this could be an important area for additional resources 
and research.
Both child (85%) and intellectual disability (77%) psychiatrists 
agreed that they would prefer to refer to a Regional Genetics Centre 
(RGC) rather than directly order a genetic test themselves; however, 
links with NHS RGCs appeared to be variable. Some respondents 
reported good links with their local genetics services, whilst others 
felt that access to services was a barrier to referring for genetic test-
ing. Both intellectual disability (83%) and child psychiatrists (72%) 
felt that better links with genetics services would be beneficial. 
Many of these clinicians felt that they do not have the knowledge 
or training to order genetic tests directly. This finding is supported 
by another survey, which found intellectual disability psychiatrists 
lacked adequate knowledge about genetics and testing processes 
(de Villiers & Porteous, 2012).
The majority of respondents expressed a wish for further train-
ing (71% child, 66% intellectual disability). Neither child and ado-
lescent nor intellectual disability psychiatry curricula currently have 
learning objectives that specifically cover genetic disorders asso-
ciated with intellectual disability (http://www.rcpsych.ac.uk/train-
inpsychiatry/corespecialtytraining/curricula.aspx). The curricula 
also fail to cover the genetic work- up and basic genetic counselling 
skills that are required to take more of an active role in identify-
ing and managing patients with genetic disorders. However, there 
are several recent initiatives to improve the psychiatry curriculum. 
For example, the Gatsby- Wellcome initiative aimed to ensure that 
training focuses more on scientific advances in basic and clinical 
neurosciences (http://www.rcpsych.ac.uk/traininpsychiatry/core-
specialtytraining/neuroscienceproject.aspx). It is, therefore, hoped 
that future cohorts of psychiatrists will be more confident in uti-
lizing technological advancements in the assessment and manage-
ment of their patients.
One of the reasons for undertaking genetic investigations is that 
a genetic diagnosis is likely to provide information about specific as-
sociated medical and psychiatric phenotypes and thus could improve 
treatment plans and clinical management for the patient. Whilst the 
majority of respondents felt that a genetic diagnosis would help with 
clinical management, fewer patients on their caseloads had a genetic 
diagnosis than they would expect, and clinical management changes 
following genetic diagnoses were not frequently seen in practice. 
There are published medical guidelines available for several genetic 
disorders, for example via the Orphanet portal for rare diseases (http://
www.orpha.net/), and information guides on an extensive range of 
chromosomal disorders are available from the support group Unique 
(http://www.rarechromo.co.uk/html/DisorderGuides.asp). It would be 
of interest for further research to investigate whether psychiatrists are 
aware of these guidelines when they receive a genetic diagnosis for 
their patient.
Another important consideration is that knowledge of behavioural 
phenotypes can place psychiatrists in a better position to deliver 
appropriate interventions and environmental adaptations. Whilst 
there is within syndrome variation it has been shown that certain be-
havioural features, such as repetitive and self- injurious behaviours, are 
more common in particular syndromes. There are also implications for 
health screening, for example gastro- intestinal problems are common 
in Cornelia de Lange syndrome and can exasperate self- injurious be-
haviours (Waite et al., 2014). A recent survey of intellectual disability 
professionals found that nine out of ten professionals interviewed felt 
that specific knowledge of a neurodevelopmental syndrome should 
play a key role in healthcare provision. A specific genetic diagnosis 
was thought to prompt proactive screening for related physical and 
mental health problems, which is of particular benefit for patients with 
severe impairments (Redley, Pannebakker, & Holland, 2016). One of 
the main challenges in practice is that individual syndromes are rare 
and psychiatrists are unlikely to care for many individuals with the 
same disorder, although the overall burden of rare syndromic disor-
ders is large.
Both child and intellectual disability psychiatrists agreed that 
receiving a genetic diagnosis was more beneficial for family members 
than for the patient. Research has shown that there is a benefit to 
mothers in receiving a diagnosis for a child with intellectual disability; 
however, there is a lack of research as to the impact of a genetic diag-
nosis for adults with intellectual disability (Lingen et al., 2016) Several 
respondents reported that a diagnosis can help to alleviate guilt for 
family members, as well as increasing understanding of the patient’s 
syndrome- specific behaviours and enabling valuable access to support 
groups. It seems that respondents were able to report on a range of 
psychosocial benefits, which could indirectly improve patient manage-
ment; however, tangible changes in clinical decision making following 
a genetic diagnosis were less easy to define.
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4.1 | Limitations
The survey was self- reported which could have led to biases in esti-
mations. There may have been a selection bias in the clinicians who 
chose to respond to the survey, perhaps those with more extreme 
views on genetics were more inclined to respond. This survey specifi-
cally focused on psychiatrists, who are one of the medical specialists 
frequently in contact with patients with intellectual disability in the 
UK. These findings may not be generalisable to other countries where 
services are organized differently.
5  | CONCLUSIONS
Whilst a high number of child and intellectual disability psychiatrists 
appear to already be ordering genetic tests there remains a prefer-
ence for referring directly to clinical genetics services. Respondents 
highlighted several areas of the genetic testing process in which they 
particularly lack confidence, such as indications for testing, interpreta-
tion and feedback of genetic results. Child psychiatrists in particular 
felt less confident, ordered fewer genetic tests, and referred fewer 
patients to genetic services.
Genetic investigations are continuing to advance at a very rapid pace, 
with exome and whole- genome sequencing beginning to enter clinical 
practice. In conjunction with other genetic investigations, it is likely that 
a genetic diagnosis will be identifiable in a much higher proportion of 
patients with intellectual disability in the future. This should facilitate 
early diagnosis and tailored interventions for patients and their families. 
However, as the landscape of genetic investigations becomes more com-
plex it is going to be a challenge for psychiatrists to keep pace of devel-
opments. Improvements in training and closer links with genetics services 
would appear to be key areas to address to meet this challenge.
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APPENDIX 
SURVEY ON ATTITUDES OF CLINICIANS TOWARDS GENETIC TESTING IN PEOPLE WITH 
INTELLECTUAL DISABILITIES
1) What is your profession?
□	Doctor	working	in	psychiatry	of	intellectual	disability
□	Doctor	working	in	child	and	adolescent	psychiatry
□	Other	please	specify:______________________________________________________
2) Where do you work?
□	Scotland
□	England
□	Northern	Ireland
□	Wales
□	Other	please	specify:______________________________________________________
3) What is your gender?
□	Female
□	Male
□	I	prefer	not	to	state
4) In what setting do you work?
□	Community	team
□	Specialist	referral	centre	(outpatient)
□	Specialist	referral	centre	(inpatient)
□	Other	please	specify:______________________________________________________
5) Years working in your specialty?
____years
6) How many patients with developmental delay/ID have you seen in the last 12 months in the following categories approximately (please state a number 
for each category)?
• Number of children (0-12 years):__________
• Number of adolescents (>12-18 years): __________
• Number of adults (>18 years): __________
7) In general do you think making a genetic diagnosis would help with management of your patients?
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
□ □ □ □ □
8) I estimate that there is a significant genetic contribution towards the cause of the ID in …. % people with ID:
• ______________% of people with ID.
9) I estimate that a significant genetic contribution towards the cause of the ID has been identified in…. % of my patients:
• ______________% of my patients.
10) Have you ever ordered a genetic test/made a referral to a geneticist in a patient with an intellectual disability?
□	Yes
□	No-                   	please continue with question 21
11) Please estimate how many patients with ID you have referred to a genetics clinic in the last year (please state a number)?
• ______________(number of patients).
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12) Reasons for genetic testing/referral to genetics?
Very frequently Frequently Occasionally Rarely Very rarely
Intellectual disability: □ □ □ □ □
Psychiatric disorder: □ □ □ □ □
Medical conditions: □ □ □ □ □
Prediction of risk for □ □ □ □ □
Inheritance of family member:
Family planning of the patient: □ □ □ □ □
Dysmorphic Features: □ □ □ □ □
Pharmacological treatment: □ □ □ □ □
Other: □ □ □ □ □
Other (please specify):_______________________________________________________________
13) Have you directly ordered a genetic test in a patient with ID in the last 10 years?
□	Yes
□	No-                               	please continue with question 17
14) Please estimate how many genetic tests have you ordered directly in patients with ID/developmental delay in the last 12 months/last 10 years ap-
proximately (please state a number):
• Last 12 months (number of tests):__________
• Last 10 years (number of tests): __________
15) Please indicate which of the following tests you have ordered in patients with ID (please tick all that apply)?
□	Karyotype	analysis
□	MLPA
□	FISH
□	Single	gene	mutation	detection
□	Array	CGH
□	Other,	please	state:	___________________________________________________________
16) Please indicate your first line genetic investigations in patients with ID/developmental delay (please tick all that apply)?
□	Karyotype	analysis
□	MLPA
□	FISH
□	Single	gene	mutation	detection
□	Array	CGH
□	Not	applicable
□	Other,	please	state:	___________________________________________________________
17) Has the genetic information changed your management?
Very frequently Frequently Occasionally Rarely Very rarely
□ □ □ □ □
18) I have used the following to aid communication in genetic counselling (please tick all that apply):
□	Videos
□	Easy	read	material
□	Speech	and	Language	Therapist
□	None	of	the	above
□	Other,	please	state:	___________________________________________________________
19) Generally I feel a genetic diagnosis has been helpful to the patient with ID:
Strongly disagree Disagree Neither agree nor disagree Agree Strongly agree
□ □ □ □ □
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20) Generally I feel a genetic diagnosis has been helpful for the patient’s family:
Strongly disagree nor disagree Neither agree Agree Strongly agree
□ □ □ □ □
21) Thinking about the assessment process in CHILDREN/ADOLESCENTS with ID: I feel confident in (not applicable = N/A):
N/A Strongly 
Disagree
Disagree Neither Agree 
nor disagree
Agree Strongly Agree
Knowledge of 
indications/ 
genetic tests:
□ □ □ □ □ □
Assessing for 
dysmorphic 
features:
□ □ □ □ □ □
Genetic 
counselling: 
□ □ □ □ □ □
Assessment of 
capacity to 
consent:
□ □ □ □ □ □
Ordering 
genetics tests:
□ □ □ □ □ □
Interpreting 
genetic test 
results: 
□ □ □ □ □ □
Feedback to 
patients:
□ □ □ □ □ □
Feedback to 
family / carers:
□ □ □ □ □ □
22) Thinking about the assessment process in ADULTS with ID: I feel confident in (not applicable = N/A):
N/A Strongly 
Disagree
Disagree Neither Agree 
nor disagree
Agree Strongly Agree
Knowledge of 
indications/ 
genetic tests:
□ □ □ □ □ □
Assessing for 
dysmorphic 
features:
□ □ □ □ □ □
Genetic 
counselling: 
□ □ □ □ □ □
Assessment of 
capacity to 
consent:
□ □ □ □ □ □
Ordering 
geneticstests:
□ □ □ □ □ □
Interpreting 
genetictest 
results: 
□ □ □ □ □ □
Feedback to 
patients:
□ □ □ □ □ □
Feedback to 
family / carers:
□ □ □ □ □ □
23) I think closer links with the regional genetics service would be helpful:
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
□ □ □ □ □
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24) I prefer to refer to a genetics clinic (rather than ordering the tests myself):
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
□ □ □ □ □
25) I would like further training in clinical genetics:
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
□ □ □ □ □
26) I am concerned about the following with respect to genetic testing in ID:
Strongly Agree Agree Neither Agree nor 
disagree
Disagree Strongly Disagree
Stigma of patients/
families:
□ □ □ □ □
Lack of available 
treatment:
□ □ □ □ □
Lack of resources: □ □ □ □ □
Implications for 
insurance:
□ □ □ □ □
Misuse of results: □ □ □ □ □
Difficulty of 
obtaining a family 
history:
□ □ □ □ □
Obtaining a sample: □ □ □ □ □
Issues around 
counselling:
□ □ □ □ □
Issues around 
capacity to 
consent:
□ □ □ □ □
Other: □ □ □ □ □
Other (please specify):_______________________________________________________________
27) Any other specific benefits that came out of genetic testing:
28) Any other suggestions/comments?
